[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100535964":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":22,"locations":30,"responsibleParty":53,"collaborators":10,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":10,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":10,"enrollmentInfo":64,"targetDuration":10,"studyType":67,"phases":10,"briefSummary":68,"conditions":69,"keywords":10,"overallStatus":45,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Participants diagnosed with moderate-to-severe plaque psoriasis",null,[12],"Drug: Deucravacitinib",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","Deucravacitinib","As per product label",[9],[20],{"name":5,"affiliation":5,"role":21},"STUDY_DIRECTOR",[23,28],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"BMS Study Connect Contact Center www.BMSStudyConnect.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":29,"role":25,"phone":10,"phoneExt":10,"email":10},"First line of the email MUST contain NCT # and Site #.",[31,43],{"facility":32,"status":33,"city":34,"state":10,"zip":35,"country":36,"countryCode":10,"cosmosGeoPoint":37,"geoPoint":42,"contacts":10},"Local Institution - 0001","WITHDRAWN","Seoul","06234","South Korea",{"type":38,"coordinates":39},"Point",[40,41],126.9784,37.566,{"lat":41,"lon":40},{"facility":44,"status":45,"city":34,"state":10,"zip":35,"country":36,"countryCode":10,"cosmosGeoPoint":46,"geoPoint":48,"contacts":49},"Novotech Laboratory Korea Co., Ltd.","RECRUITING",{"type":38,"coordinates":47},[40,41],{"lat":41,"lon":40},[50],{"name":51,"role":25,"phone":52,"phoneExt":10,"email":10},"South Korea Generic Country, Site 0002","0000000000",{"type":54,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100535964","real-world-safety-and-effectiveness-of-sotyktu-deucravacitinib-in-patients-with-moderate-to-severe-plaque-psoriasis-in-korea-100535964",false,"NCT06258668","Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea","Sotyktu (Deucravacitinib) Post-Marketing Surveillance in Korean Patients With Moderate-to-Severe Plaque Psoriasis","Inclusion Criteria:\n\n* Adult participants ≥19 years of age\n* Diagnosis of moderate-to-severe plaque psoriasis\n* Candidate for phototherapy or systemic therapy\n* Will begin deucravacitinib according to approved product label\n\nExclusion Criteria:\n\n* Participants prescribed deucravacitinib for therapeutic indications not approved in Korea\n* Participants for whom deucravacitinib is contraindicated as clarified in Korean prescribing information by ministry of food and drug safety (MFDS)","ALL","19 Years",{"count":65,"type":66},505,"ESTIMATED","OBSERVATIONAL","The purpose of this observational study is to describe the safety and effectiveness of deucravacitinib in participants in Korea that have been diagnosed with moderate-to-severe plaque psoriasis.",[70],"Moderate-to-severe Plaque Psoriasis","2024-11-05",{"date":73,"type":74},"2024-11-06","ACTUAL",{"date":76,"type":74},"2024-08-21",{"date":78,"type":66},"2028-09-30",{"name":5,"class":6},2]